Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05408663 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of EXT608 in Healthy Adults
A Phase 1 study of Safety Issues, sponsored by Extend Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05408663 is a Phase 1 study of Safety Issues that has completed, run by Extend Biosciences. The registered enrollment target is 24 participants, below the 118-participant average among 13 other Safety Issues trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05408663, a Phase 1 study of Safety Issues, has completed, sponsored by Extend Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose safety and tolerability study of EXT608 in healthy subjects. There will be up to 6 sequential dose escalation cohorts of 4 participants. In each cohort 3 participants will receive EXT608 and 1 participant will receive placebo.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG EXT608
Study Locations (1)
Kansas
- PRA - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-07-21 |
| Est. Completion | 2023-06-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05408663
The ClinicalTrials.gov registry entry for NCT05408663 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 118-participant average among 13 other Safety Issues trials with a reported enrollment target (80% lower). The listed sponsor is Extend Biosciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Safety Issues appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05408663 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT05408663 about?
NCT05408663 is a clinical study titled "A Phase 1 Study of EXT608 in Healthy Adults". This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose safety and tolerability study of EXT608 in healthy subjects. There will be up to 6 sequential dose escalation cohorts of 4 participants. In each cohort 3 participants will receive EXT608 and 1 participant will rec...
What is the current status of trial NCT05408663?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-07-21. Estimated completion is 2023-06-13.
What conditions does trial NCT05408663 study?
This clinical trial studies the following conditions: Safety Issues.
What interventions are being tested in trial NCT05408663?
The interventions under investigation include: Placebo (OTHER), EXT608 (DRUG).
Who is sponsoring clinical trial NCT05408663?
This trial is sponsored by Extend Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05408663 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Safety Issues
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1 Study of the Safety and Tolerability of ICM20 in Adults
ACTIVE NOT RECRUITING · Phase 1
-
Rectal Insert TAF/EVG Pre-Exposure Prophylaxis (RITE PrEP) Study
COMPLETED · Phase 1
-
Oral Remimazolam With and Without Alcohol in Healthy Female Subjects
COMPLETED · Phase 1
-
Pupillary Unrest in Ambient Light, and Relationship to Opioid-Induced Respiratory Depression
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.